Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice.
Interleukin (IL)-18 exhibits antitumor as well as antiosteoclastogenic activities. These findings suggest that IL-18 is a potential tool for the treatment of cancers with associated osteolytic bone metastasis. We have previously shown that systemic daily administration of recombinant (r) IL-18 inhibits the development of osteolytic bone metastasis by human breast cancer cells. Here we demonstrate that systemic daily administration of rIL-18 (1 microg/mouse/d) for 21 days significantly inhibited the number and the total area of osteolytic bone metastasis by RWGT2 human lung cancer cells in nude mice. No severe adverse effects were observed. Natural killer (NK) cells did not increase in splenocytes from rIL-18-treated mice, and the in vitro NK activity of splenocytes against RWGT2 cells was only weakly enhanced in the presence of IL-18. The administration of rIL-18 made no difference in the growth of subcutaneous tumors, histologic indices (mitotic index, apoptotic index, and Ki-67-labeling index) of subcutaneous tumors or metastatic bone foci, or in the number of osteoclasts along the bone surface adjacent to tumors. Moreover, serum levels of cytokines including interferon-gamma, IL-1alpha, IL-6, tumor necrosis factor-alpha, and granulocyte/macrophage colony-stimulating factor, which regulate bone-resorbing activity of osteoclasts, were evaluated. Among them, IL-6 was remarkably downregulated in rIL-18-treated mice. These findings suggest that IL-18 inhibits osteolytic bone metastasis possibly through suppression of osteoclastic bone-resorption mediated in part by IL-6.
Iwasaki
Teruo
T
First Department of Pathology, Hyogo College of Medicine, Nishinomiya, Japan.
Yamashita
Kunihiro
K
Tsujimura
Tohru
T
Kashiwamura
Shin-ichiro
S
Tsutsui
Hiroko
H
Kaisho
Tsuneyasu
T
Sugihara
Ayako
A
Yamada
Naoko
N
Mukai
Mutsuko
M
Yoneda
Toshiyuki
T
Okamura
Haruki
H
Akedo
Hitoshi
H
Terada
Nobuyuki
N
D000818:Animals; D001859:Bone Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000556:secondary*; D001862:Bone Resorption / Q000517:prevention & control; D016207:Cytokines / Q000032:analysis / Q000187:drug effects; D004195:Disease Models, Animal; D006801:Humans; D007371:Interferon-gamma / Q000032:analysis / Q000187:drug effects; D020382:Interleukin-18 / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D051379:Mice; D008805:Mice, Inbred A; D009368:Neoplasm Transplantation; D010014:Osteolysis / Q000517:prevention & control; D011336:Probability; D012680:Sensitivity and Specificity; D018709:Statistics, Nonparametric; D014407:Tumor Cells, Cultured
D016207:Cytokines; D020382:Interleukin-18; D007371:Interferon-gamma